LAS1L: A Potential Drug Target and Biomarker (G81887)

Target Name: LAS1L

NCBI ID: G81887

LAS1L

LAS1L: A Potential Drug Target and Biomarker

Introduction

LAS1L (Lac-Aspartate-Sulfurase 1-Like) is a gene that encodes a protein known as LAS1L, which is expressed in various tissues and organs throughout the body. LAS1L is a member of the Aspartate-Sulfurase gene family, which is involved in the regulation of aspartate, a crucial amino acid that plays a vital role in various cellular processes. The aspartate pathway is a highly conserved network of enzymes that have been identified as potential drug targets in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The LAS1L gene has been gaining attention due to its potential as a drug target. Several studies have suggested that LAS1L may be involved in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Additionally, LAS1L has been shown to play a key role in the regulation of cellular processes that are relevant to a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Potential Drug Targets

LAS1L is a potential drug target due to its involvement in the regulation of aspartate metabolism. Aspartate is a crucial amino acid that plays a vital role in various cellular processes, including cell signaling, DNA replication, and neurotransmitter synthesis. LAS1L is involved in the regulation of aspartate metabolism by promoting the conversion of aspartate to aspartate-glutaric acid via the aspartate-glutaric acid transporter (ASGAT). This transporter is expressed in various tissues and organs throughout the body and is involved in the regulation of aspartate homeostasis.

Studies have shown that LAS1L is involved in the regulation of aspartate metabolism, which is critical for the development and progression of various diseases. For example, LAS1L has been shown to play a key role in the regulation of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, LAS1L has been shown to be involved in the regulation of cancer development and progression, including the regulation of cell proliferation and apoptosis.

Biomarkers

LAS1L has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. LAS1L has also been shown to be expressed in various tissues and organs, including brain, spinal cord, muscle, liver, and pancreas, which suggests that it may be a useful biomarker for these diseases. Additionally, LAS1L has been shown to be involved in the regulation of cellular processes that are relevant to a variety of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This suggests that LAS1L may be a useful biomarker for these diseases as well.

Conclusion

In conclusion, LAS1L is a gene that encodes a protein involved in the regulation of aspartate metabolism and has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Additionally, LAS1L has been shown to be a potential biomarker for these diseases. Further research is needed to fully understand the role of LAS1L in these diseases and to develop effective therapies targeting LAS1L.

Protein Name: LAS1 Like Ribosome Biogenesis Factor

Functions: Involved in the biogenesis of the 60S ribosomal subunit. Required for maturation of the 28S rRNA. Functions as a component of the Five Friends of Methylated CHTOP (5FMC) complex; the 5FMC complex is recruited to ZNF148 by methylated CHTOP, leading to desumoylation of ZNF148 and subsequent transactivation of ZNF148 target genes

The "LAS1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LAS1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets